|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2008-2-18
|
|
pubmed:abstractText |
We investigated the organ-reducing ability of 1,2-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridine-dicarboxylic acid methyl 6-(5-phenyl-3-pyrazolyloxy) hexyl ester (CV159) that exhibits selective blocking of Ca(2+)/calmodulin and inhibition of Ca(2+) overloading in living organisms (Sprague Dawley rats) using an in vivo and an ex vivo electron paramagnetic imaging technique. Decay rates in CV159-treated rats were significantly higher than those in untreated rats and were almost equal to those in the sham group. Both cytosol and mitochondrial superoxide scavenging activity in CV159-treated rats were significantly higher than those in untreated rats, and cytosol superoxide scavenging activity only was slightly higher than that in the sham group. Faint staining for anti-superoxide dismutase antibody was markedly observed in necrotic lesions in the liver of control group. Alanine aminotransferase level in CV-treated rats were significantly decreased as compared with the levels in untreated rats. Electron microscopy showed a decreased number of damaged mitochondria, whereas mitochondrial damage was significantly reduced in CV-treated animals. We conclude that CV159 retains the organ-reducing activity against radicals in hepatic I/R injury that is mediated by the inhibition of Ca(2+) overloading.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
0022-4804
|
|
pubmed:author |
pubmed-author:AsakuraTakeshiT,
pubmed-author:AsanoTakayukiT,
pubmed-author:IshiuchiAtsukoA,
pubmed-author:JinnouchiYujiY,
pubmed-author:KamibayashiMasatoM,
pubmed-author:KobayashiHiromichi PHP,
pubmed-author:KoizumiSatoshiS,
pubmed-author:KubotaSunaoS,
pubmed-author:NakanoHiroshiH,
pubmed-author:OowadaShigeruS,
pubmed-author:OtsuboTakehitoT,
pubmed-author:ShimamuraTsukasaT,
pubmed-author:WatanabeTaijiT
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
145
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
49-56
|
|
pubmed:dateRevised |
2009-11-19
|
|
pubmed:meshHeading |
pubmed-meshheading:18067923-Alanine Transaminase,
pubmed-meshheading:18067923-Animals,
pubmed-meshheading:18067923-Calcium,
pubmed-meshheading:18067923-Calmodulin,
pubmed-meshheading:18067923-Dihydropyridines,
pubmed-meshheading:18067923-Disease Models, Animal,
pubmed-meshheading:18067923-Electron Spin Resonance Spectroscopy,
pubmed-meshheading:18067923-Liver,
pubmed-meshheading:18067923-Male,
pubmed-meshheading:18067923-Mitochondria,
pubmed-meshheading:18067923-Myosin-Light-Chain Kinase,
pubmed-meshheading:18067923-Oxidative Stress,
pubmed-meshheading:18067923-Rats,
pubmed-meshheading:18067923-Rats, Sprague-Dawley,
pubmed-meshheading:18067923-Reactive Oxygen Species,
pubmed-meshheading:18067923-Reperfusion Injury,
pubmed-meshheading:18067923-Survival Rate
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
The role of the new Ca2+ antagonist, CV159, in hepatic I/R injury-the evaluation of hepatic organ reducing activity using in vivo and ex vivo EPR.
|
|
pubmed:affiliation |
Department of Gastroenterological Surgery, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan.
|
|
pubmed:publicationType |
Journal Article
|
